FDA approves OTC opioid overdose reversal drug
The Brown University Child & Adolescent Psychopharmacology Update · 2026-08 · 28 (8) · 7-8
DOI: 10.1002/cpu.31082 ↗At a glance
Journal article in The Brown University Child & Adolescent Psychopharmacology Update, published online on 2026-07-29.
Abstract (original language)
On June 16, the Food and Drug Administration (FDA) approved over‐the‐counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump's Great American Recovery Initiative , a federal effort to address the U.S. addiction and substance use disorder crisis and coordinate the government's approach to prevention, treatment, and long‐term recovery.
Cite
APA
(2026). FDA approves OTC opioid overdose reversal drug. The Brown University Child & Adolescent Psychopharmacology Update, 28(8), 7-8. https://doi.org/10.1002/cpu.31082
Vancouver
FDA approves OTC opioid overdose reversal drug. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(8):7-8. doi:10.1002/cpu.31082
BibTeX
@article{euvimed2026,
title = {FDA approves OTC opioid overdose reversal drug},
journal = {The Brown University Child & Adolescent Psychopharmacology Update},
year = {2026},
volume = {28},
number = {8},
pages = {7--8},
doi = {10.1002/cpu.31082}
}
EUVIMED